VAST™ Space by XtalPi

Virtual, Automated, Swift, and Tailored for drug discovery

XtalPi's VAST™ Space (Virtual, Automated, Swift, and Tailored) is a collection of over 4.66 billion novel, synthetically accessible compounds for early-stage drug discovery. Powered by next-generation automation, proprietary data, and AI, it provides an actionable universe of drug-like molecules that can be synthesized, ordered, and delivered to your lab. Delivery is typically completed within 2 to 4 weeks with an average success rate of over 85%.

Built on Automation, AI, and Proprietary Data

VAST™ Space is built from XtalPi’s validated reaction protocols using in-stock building blocks, with synthetic accessibility assessed against the company’s proprietary reaction data

40+
Validated reaction protocols, 1 to 2 synthetic steps
58,000
In-stock building blocks
4.66 B
Virtual products, searchable and orderable

Fulfillment is driven by XtalPi's automated lab clusters, operating 24/7 under AI-guided scheduling.

What Makes VAST Space Unique?

By pairing validated chemistry with in-stock materials, VAST™ Space ensures high synthetic accessibility. This alignment provides a direct, reliable path from in silico hit to delivered compound.

  • Validated synthetic accessibility: Every compound relies on 40+ validated reaction protocols and 58,000 in-stock building blocks, requiring only 1 to 2 steps.
  • Automated fulfillment: Production utilizes several workstations running 24/7 under AI scheduling. Typical lead time is 2 to 4 weeks with a success rate above 85%.
  • Novel chemical territory: Spans regions distinct from standard commercial offerings, featuring unique molecular graphs
  • Drug-discovery-ready: All candidates meet drug-like filters with PAINS structural alerts removed.

Profile and Properties of the VAST™ Space

The 4.66 billion compounds in VAST™ Space feature property profiles aligned with standard small-molecule drug discovery. The Space covers familiar lead-like parameters while offering the necessary breadth to explore beyond Rule of 5 (Ro5) boundaries.

Property distributions were computed using SpaceProp, developed by the ZBH at Universität Hamburg (Bellmann, Klein, Rarey, J. Chem. Inf. Model. 2022; Lübbers, Lessel, Rarey, J. Chem. Inf. Model. 2024).

Key property highlights:

  • 95% Veber-compliant: Most compounds satisfy Veber criteria for oral bioavailability regarding rotatable bonds and TPSA.
  • Optimal H-bond profile: Hydrogen bond donors and acceptors align with permeable, drug-like ranges.
  • Targeted molecular weight: Most structures center between 350 and 550 Da, leaving ample room for lead-like exploration.

Eager to learn more?